INMUNOTEK at the EAACI congress

INMUNOTEK has been present at the EAACI congress held in Lisbon in the commercial exhibition area. The annual conference of the EAACI (European Academy of Allergy and Clinical Immunology) is one of the most important events in the field of allergy and immunology worldwide. With a participation of more than 7,000 delegates and a high scientific and commercial level, the annual congress is the most outstanding event of the EAACI.

Comunidad Madrid

Visit of the Regional Minister of Health

The Regional Minister of Health of the Community of Madrid, Enrique Ruiz Escudero, has visited INMUNOTEK after receiving the CEIM award as the best innovative company. The visit was accompanied by Luisa María Fernanda, General Director of Madrid Activa. After a presentation of the company by José Luis Subiza, CEO-President of INMUNOTEK, a visit was made to the production facilities and the R&D laboratories.

INMUNOTEK revalidates its Innovative SME stamp

,

INMUNOTEK revalidates its Innovative SME stamp issued by the Spanish Government at the Directorate General for Innovation and Competitiveness of the Ministry of Economy. This stamp was granted to INMUNOTEK in 2015.

Premios CEIM Inmunotek

INMUNOTEK best innovative company

INMUNOTEK is awarded as Best Innovative Company and distinguished as one of the three companies with the largest International Expansion, in the first edition of the CEIM-CEOE Awards. This recognition is given to companies that have stood out, both for their contribution to economic development, the creation of employment and for their work at the service of the community. Javier Ruiz, Deputy Minister of Economy and Competitiveness of the Community of Madrid has been in charge of giving the award to Dr. Enrique Fernández Caldas, Scientific Director of INMUNOTEK.

Ministerio

RETOS-COLABORACION 2017 Grant

The Spanish Ministry of Science, Innovation and Universities has granted the funding of a research project for the development of a new biomarker in prostate cancer. The application was submitted by INMUNOTEK together with the ICSCYL Foundation to Retos-Colaboracion 2017 grant program.

Alergia e Inmunologia

INMUNOTEK at the EAACI 2018 congress

INMUNOTEK has been present at the annual conference of the EAACI (European Academy of Allergy and Clinical Immunology). The current edition, EAACI 2018, has taken place in Munich. In addition to the commercial exhibition, INMUNOTEK has participated contributing scientifically in the form of oral communications and posters.

Patente EEUU

US patent granted

The US Patent Office has granted to INMUNOTEK the patent US9901633B2. This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.

Empresa Innovadora

INMUNOTEK has made the 2018 Inc.5000 list

,

Inc. magazine revealed the 2018 Inc. 5000 list of fastest-growing private companies in Europe.  With an accumulated growth of more than 80%, INMUNOTEK has made into this ranking.

JPO

Japan patent granted

The Japan Patent Office has granted to INMUNOTEK the patent JP6285012B2 . This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.

INMUNOTEK celebrates its 25th anniversary

INMUNOTEK has celebrated its 25th anniversary on December 1st with a party at the Círculo de Bellas Artes in Madrid. Its more than 200 employees have been able to enjoy an emotional event where there has been music and humor from Javier Horche and his group.